Mitogen hypotheses revisited: enhancement of allograft tolerance and replacement of transplantation procedures in treating cancer.
Wimer
B M
BM
JBMW Immunotherapeutics, Albuquerque, NM 87123-4255, USA.
D000069594:Abatacept; D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use*; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000276:immunology*; D060908:CTLA-4 Antigen; D006082:Graft Enhancement, Immunologic; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects*; D018796:Immunoconjugates; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects*; D008934:Mitogens / Q000494:pharmacology / Q000627:therapeutic use*; D018448:Models, Immunological; D010835:Phytohemagglutinins / Q000494:pharmacology / Q000627:therapeutic use; D014184:Transplantation, Homologous / Q000276:immunology*
D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D008934:Mitogens; D010835:Phytohemagglutinins; D000069594:Abatacept